Recombinant Human IL-2 (carrier-free)

Pricing & Availability
Regulatory Status
Other Names
T-cell growth factor (TCGF), Eosinophil differentiation factor (EDF), Killer cell helper factor (KHF), Macrophage-activating factor for cytotoxicity I (MAF-C I), Thymocyte differentiation factor (TDF)
Ave. Rating
Submit a Review
Product Citations
Recombinant Human IL-2 induces the proliferation of mouse HT-2 cells in a dose-dependent manner. The ED50 for this effect is 0.2 – 1.0 ng/mL.
  • Human_IL-2_CF_RECOM_1_043019.png
    Recombinant Human IL-2 induces the proliferation of mouse HT-2 cells in a dose-dependent manner. The ED50 for this effect is 0.2 – 1.0 ng/mL.
Cat # Size Price Quantity Check Availability Save
589102 10 µg £101
Check Availability

Need larger quantities of this item?
Request Bulk Quote
589104 25 µg £182
Check Availability

Need larger quantities of this item?
Request Bulk Quote
589106 100 µg £478
Check Availability

Need larger quantities of this item?
Request Bulk Quote
589108 500 µg £1523
Check Availability

Need larger quantities of this item?
Request Bulk Quote

IL-2 was discovered through its function as a T cell growth factor (TCGF), and plays a pivotal role in immune responses against pathogenic infection. Recognition and binding of the foreign Ags by the TCRs stimulate both the secretion of IL-2 and the expression of IL-2Rs on the T cell surface. Subsequently, the IL-2/IL-2R interaction activates the intracellular Ras/Raf/MAPK, JAK/STAT, and PI3K/AKT signal pathways, and ultimately stimulates the growth, differentiation, and survival of the Ag-selected cytotoxic T cells. Human IL-2 acts on murine and human T cells, and its receptors are shared by others cytokines. IL-2Rα is an IL-2–specific receptor, IL-2Rβ is shared with IL-15 and the γ chain that is a common receptor shared by many cytokines including IL-2, IL-4, IL-7, IL-9, IL-15, and IL-21.

Product Details
Technical Data Sheet (pdf)

Product Details

Human IL-2, amino acids Ala21-Thr153 (Accession # NM_000586), was expressed in insect cells.
Molecular Mass
The 133 amino acid recombinant protein (Ala21-Thr153) has a predicted molecular mass of 15418 Da. The DTT-reduced and the non-reduced protein migrate at approximately 15 kD by SDS-PAGE. The N-terminal amino acid is Ala.
Purity is >95%, as determined by Coomassie stained SDS-PAGE.
The protein was 0.22 µm filtered protein solution is in 0.1% TFA, 30% acetonitrile.
Endotoxin Level
Less than 0.01 ng per µg cytokine as determined by the LAL method.
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling
Unopened vial can be stored between 2°C and 8°C for up to 2 weeks, at -20°C for up to six months, or at -70°C or colder until the expiration date. For maximum results, quick spin vial prior to opening. The protein can be aliquoted and stored at -20°C or colder. Stock solutions can also be prepared at 50 - 100 µg/mL in appropriate sterile buffer, carrier protein such as 0.2 - 1% BSA or HSA can be added when preparing the stock solution. Aliquots can be stored between 2°C and 8°C for up to one week and stored at -20°C or colder for up to 3 months. Avoid repeated freeze/thaw cycles.
The ED50 = 0.05 – 0.3 ng/mL as determined by the dose-dependent stimulation of CTLL2 cell proliferation. The ED50 = 0.2 – 1.0 ng/mL as determined by the dose-dependent stimulation of HT-2 cell proliferation.

The specific activity of recombinant human IL-2 is approximately 2.36 x 104 IU/μg when compared against the 2nd WHO International Standard for Human IL-2 (NIBSC code: 86/500) as determined by dose-dependent stimulation of HT-2 cell proliferation.

For more information on specific activity, please visit the Recombinant Protein Unit Conversions page.


Application Notes

This IL-2 protein is biologically active and can be used for in vitro assays.

BioLegend carrier-free recombinant proteins provided in liquid format are shipped on blue-ice. Our comparison testing data indicates that when handled and stored as recommended, the liquid format has equal or better stability and shelf-life compared to commercially available lyophilized proteins after reconstitution. Our liquid proteins are verified in-house to maintain activity after shipping on blue ice and are backed by our 100% satisfaction guarantee. If you have any concerns, contact us at

Application References

(PubMed link indicates BioLegend citation)
  1. Wingender G, et al. 2011. J. Exp. Med. 208:1151. PubMed
Product Citations
  1. Aguilar Díaz De León JS, et al. 2021. J Cancer. 12:4993. PubMed
  2. Zhang Z, et al. 2022. Cancer Gene Ther. 29:722. PubMed
  3. Zhang Y, et al. 2022. Nat Med. 28:1421. PubMed
  4. Law AMK, et al. 2022. Adv Sci (Weinh). 9:e2103332. PubMed
  5. Kim HS, et al. 2023. Bioact Mater. 21:241. PubMed
  6. Islam M, et al. 2023. Aliment Pharmacol Ther. 57:689. PubMed
  7. Ogura H, et al. 2022. Nat Commun. 13:7063. PubMed
  8. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  9. Sungur CM, et al. 2022. J Clin Invest. Online ahead of print. PubMed
  10. Yoon HJ, et al. 2022. Exp Mol Med. Online ahead of print. PubMed
  11. Tang M, et al. 2019. Biomed Res Int. 2019:1050285. PubMed
  12. Jowett GM, et al. 2022. Cell Rep. 40:111281. PubMed
  13. Wongchang T, et al. 2023. Sci Rep. 13:7058. PubMed
  14. Schank M, et al. 2023. Viruses. 15:. PubMed
  15. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
  16. Zhou Z, et al. 2021. Nat Biomed Eng. 5:1320. PubMed
  17. Wu SY, et al. 2021. J Immunother Cancer. 9: . PubMed
  18. Lin YZ, et al. 2022. Comput Struct Biotechnol J. 20:241. PubMed
  19. Yi K, et al. 2022. Front Immunol. 12:802795. PubMed
  20. Boothby IC, et al. 2021. Nature. 599:667. PubMed
  21. Liu Y, et al. 2018. JCI Insight. 3:. PubMed
  22. Zhao J, et al. 2021. Front Immunol. 12:658420. PubMed
  23. Schiferle EB, et al. 2021. Sci Adv. 7: . PubMed
  24. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  25. Khanam A, et al. 2021. Front Immunol. 11:599648. PubMed
  26. Li C, et al. 2021. J Immunother Cancer. 9:. PubMed
  27. Cho A, et al. 2019. Cell Rep. 28:909. PubMed
  28. Hutcherson SM, et al. 2021. J Immunol. 207:1150. PubMed
  29. Baleeiro RB, et al. 2022. Oncoimmunology. 11:2080329. PubMed
  30. Rodda LB, et al. 2020. Cell. 184(1):169-183.e17. PubMed
  31. Hurrell BP, et al. 2019. Cell Rep. 29:4509. PubMed
  32. Rafieerad A, et al. 2021. Adv Funct Mater. 31:2106786. PubMed
  33. Muik A, et al. 2022. J Immunother Cancer. 10:. PubMed
  34. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  35. Guo J, et al. 2019. Cancer Immunol Res. 1.349305556. PubMed
  36. Shang M, et al. 2021. Nat Commun. 12:1940. PubMed
  37. Xhangolli I, et al. 2019. Genomics Proteomics Bioinformatics. 17:129. PubMed
  38. Rodda LB, et al. 2020. medRxiv. . PubMed
  39. Henrich IC, et al. 2021. Cancer Res. 81:2171. PubMed
  40. Pepper M, et al. 2020. Res Sq. . PubMed
  41. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
  42. Ren X, et al. 2022. STAR Protoc. 3:101818. PubMed
  43. Su Y, et al. 2022. Cell. 185:881. PubMed
  44. Xu H, et al. 2021. J Clin Invest. 131:. PubMed
  45. Jiao S, et al. 2017. Clin Cancer Res. 23:3711. PubMed
  46. Virtakoivu R, et al. 2021. Clin Cancer Res. 27:4205. PubMed
  47. Arora S, et al. 2021. Med (N Y). 2:938. PubMed
  48. Malaker SA, et al. 2019. Proc Natl Acad Sci U S A. 116:7278. PubMed
  49. Jenks SA et al. 2018. Immunity. 49(4):725-739 . PubMed
  50. Senger K, et al. 2022. Curr Protoc. 2:e538. PubMed
  51. Vidard L, et al. 2019. J Immunol. 203:676. PubMed
  52. Malu D, et al. 2011. J Immunol. 186:6271. PubMed
  53. Wang Y, et al. 2022. Front Immunol. 12:762989. PubMed
  54. Yang JY, et al. 2020. J Cell Mol Med. . PubMed

Antigen Details


Activated T cells

IL-2 works in vivo to promote clonal T-cell expansion during immune responses. IL-2 stimulates the growth, differentiation, and survival of the Ag-selected cytotoxic T lymphocytes (CTLs). In addition, IL-2 regulates facilitate the proliferation and the synthesis of immunoglobulin by B cells, induces the generation and persistence of natural killer (NK) cells. Also, IL-2, through its role in activation-induced cell death (AICD) and its participation in the maintenance of peripheral CD4+CD25+ regulatory T (TReg) cells, is involved in the elimination of self-reactive T cells, which have a role in the pathogenesis of autoimmune diseases.
T cells, B cells, NK cells, LAK cells, monocytes, macrophages, oligodendrocytes
IL-2R is composed of three subunits, IL-2R alpha (p55, Tac Ag, or CD25), IL-2R beta (p75 or CD122), and the γc chain (p65 or CD132).
Cell Type
Embryonic Stem Cells, Hematopoietic stem and progenitors
Biology Area
Immunology, Stem Cells
Molecular Family
Antigen References

1. Smith KA. 1988. Science 240:1169.
2. D’Cruz LM, et al. 2005. Nature Immunol. 6:1152.
3. Maloy KJ, et al. 2005. Nature Immunol. 6:1071.
4. Waldmann TA. 2006. Nature Rev. Immunol. 6:595.
5. Ma A, et al. 2006. Annu. Rev. Immunol. 24:657.
6. Du J, et al. 2010. J. Immunol. 184:1361.

Gene ID
3558 View all products for this Gene ID
View information about IL-2 on

Related FAQs

Why choose BioLegend recombinant proteins?

     • Each lot of product is quality-tested for bioactivity as indicated on the data sheet.
     • Greater than 95% Purity or higher, tested on every lot of product.
     • 100% Satisfaction Guarantee for quality performance, stability, and consistency.
     • Ready-to-use liquid format saves time and reduces challenges associated with reconstitution.
     • Bulk and customization available. Contact us.
     • Learn more about our Recombinant Proteins.

How does the activity of your recombinant proteins compare to competitors?

We quality control each and every lot of recombinant protein. Not only do we check its bioactivity, but we also compare it against other commercially available recombinant proteins. We make sure each recombinant protein’s activity is at least as good as or better than the competition’s. In order to provide you with the best possible product, we ensure that our testing process is rigorous and thorough. If you’re curious and eager to make the switch to BioLegend recombinants, contact your sales representative today!

What is the specific activity or ED50 of my recombinant protein?

The specific activity range of the protein is indicated on the product datasheets. Because the exact activity values on a per unit basis can largely fluctuate depending on a number of factors, including the nature of the assay, cell density, age of cells/passage number, culture media used, and end user technique, the specific activity is best defined as a range and we guarantee the specific activity of all our lots will be within the range indicated on the datasheet. Please note this only applies to recombinants labeled for use in bioassays. ELISA standard recombinant proteins are not recommended for bioassay usage as they are not tested for these applications.

Have your recombinants been tested for stability?

Our testing shows that the recombinant proteins are able to withstand room temperature for a week without losing activity. In addition the recombinant proteins were also found to withstand four cycles of freeze and thaw without losing activity.

Does specific activity of a recombinant protein vary between lots?

Specific activity will vary for each lot and for the type of experiment that is done to validate it, but all passed lots will have activity within the established ED50 range for the product and we guarantee that our products will have lot-to-lot consistency. Please conduct an experiment-specific validation to find the optimal ED50 for your system.

How do you convert activity as an ED50 in ng/ml to a specific activity in Units/mg?

Use formula Specific activity (Units/mg) = 10^6/ ED50 (ng/mL)

Go To Top Version: 10    Revision Date: 10/26/2021

For Research Use Only. Not for diagnostic or therapeutic use.


This product is supplied subject to the terms and conditions, including the limited license, located at ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.


BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.


8999 BioLegend Way, San Diego, CA 92121
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587


Login / Register
Remember me
Forgot your password? Reset password?
Create an Account